JOHANNESBURG, March 9 (Reuters) - South African drugmaker Aspen Pharmacare Holdings Ltd reported a 6 percent rise in first-half profit on Thursday, helped by the results of a recently acquired portfolio of medicines from AstraZeneca .
Aspen, the biggest generic drugmaker in the southern hemisphere, said normalised headline earnings per share rose to 692 cents in the six months ended December 2016, from 656 cents a year earlier.
Headline EPS is the main profit measure in South Africa and strips out certain one-off items.
Aspen said the results were largely boosted by the $770 million acquisition of marketing rights to a portfolio of anaesthetics from AstraZeneca in September last year. (Reporting by Tiisetso Motsoeneng; Editing by Subhranshu Sahu)